Alumis (ALMS) Stock Price, News & Analysis

Company Overview

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Key Stats

• Today's Range: $25.95 to $28.11
• 50-Day Range: $18.99 to $28.14
• 52-Week Range: $3.20 to $30.60
• Volume: 1.40 million shs
• Average Volume: 2.17 million shs
• Market Capitalization: $3.48 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.30
• Consensus Rating: Moderate Buy

Alumis Stock Analysis - MarketRank™

Alumis scored higher than 48% of companies evaluated by MarketBeat, and ranked 466th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alumis has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Alumis has a consensus price target of $40.30, representing about 47.8% upside from its current price of $27.27.

Amount of Analyst Coverage

Alumis has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alumis are expected to grow in the coming year, from ($2.87) to ($2.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alumis is -13.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alumis is -13.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alumis has a P/B Ratio of 9.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.98% of the float of Alumis has been sold short.

Short Interest Ratio / Days to Cover

Alumis has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in Alumis has recently increased by 14.33%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alumis does not currently pay a dividend.

Dividend Growth

Alumis does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Alumis this week, compared to 4 articles on an average week.

Search Interest

Only 7 people have searched for ALMS on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.

MarketBeat Follows

3 people have added Alumis to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alumis insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.70% of the stock of Alumis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Alumis has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 7/06/2026
• Next Earnings (Estimated): 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALMS
• Previous Symbol: NASDAQ:ALMS
• CIK: 1847367
• Web: N/A
• Phone: (650) 231-6625
• Fax: N/A
• Employees: N/A
• Year Founded: 2021

Price Target and Rating

• Average Price Target for Alumis: $40.30
• High Price Target: $55.00
• Low Price Target: $25.00
• Potential Upside/Downside: +47.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$243.32 million
• Net Margins: -2,825.70%
• Pretax Margin: -2,927.59%
• Return on Equity: -88.79%
• Return on Assets: -70.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.51
• Quick Ratio: 7.51

Sales & Book Value

• Annual Sales: $8.40 million
• Price / Sales: 413.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.88 per share
• Price / Book: 9.47

Miscellaneous

• Outstanding Shares: 127,492,000
• Free Float: 84,527,000
• Market Cap: $3.48 billion
• Optionable: N/A
• Beta: -0.73